| Pegasys (pegylated interferon α -2a) / Roche |
NCT02604823: A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV) |
|
|
| Completed | 4 | 307 | RoW | Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Hepatitis B, Chronic | 11/05 | 11/05 | | |
NCT00077649: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC). |
|
|
| Completed | 4 | 188 | US | ribavirin [Copegus], peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 12/05 | 12/05 | | |
NCT01120795: Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy |
|
|
| Completed | 4 | 55 | RoW | Pegylated interferon and ribavirin, Pegasys and Copegus | Melbourne Health, The University of New South Wales, St Vincent's Hospital, Sydney, Western Hospital, Australia, Monash University, Hoffmann-La Roche | Chronic Hepatitis C | 01/06 | 07/06 | | |
NCT00087568: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin |
|
|
| Completed | 4 | 57 | US | Ribavirin, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 03/06 | 03/06 | | |
NCT00077636: ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection. |
|
|
| Completed | 4 | 1469 | US, Canada, Europe, RoW | Copegus, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 03/06 | 03/06 | | |
NCT00087607: Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC). |
|
|
| Completed | 4 | 385 | US | Ribavirin, Copegus, Peginterferon alfa-2b (PEG-Intron), Rebetol, Peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 03/06 | 04/06 | | |
NCT00475072: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C. |
|
|
| Completed | 4 | 14 | RoW | peginterferon alfa-2a [Pegasys], ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 07/06 | 07/06 | | |
NCT00087594: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program. |
|
|
| Completed | 4 | 48 | US | peginterferon alfa-2a [Pegasys], ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 10/06 | 10/06 | | |
NCT00948220: Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C |
|
|
| Completed | 4 | 26 | Europe | peginterferon alfa-2a and ribavirin, Pegasys, Copegus | University of Ulm, Hoffmann-La Roche | Hepatitis C, Chronic, Liver Diseases, Virus Diseases | 01/07 | 03/08 | | |
NCT02570191: A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV) |
|
|
| Completed | 4 | 60 | Europe | Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Hepatitis B, Chronic | 02/07 | 02/07 | | |
NCT00275548: Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C |
|
|
| Completed | 4 | 12 | US | Pegasys, peginterferon alfa-2a, Ro25-8310), Copegus, (ribavirin, Ro20-9963) | Mayo Clinic, Roche Pharma AG | Liver Transplant, Hepatitis C | 06/07 | 04/09 | | |
NCT02864199: A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment |
|
|
| Completed | 4 | 63 | US, Europe, RoW | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 09/07 | 09/07 | | |
NCT00107653: Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. |
|
|
| Completed | 4 | 569 | US | Ribavirin, Peginterferon alfa-2a | Hoffmann-La Roche | Hepatitis C, Chronic | 09/07 | 09/07 | | |
NCT00226382: Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment |
|
|
| Completed | 4 | 50 | RoW | Pegylated Interferon-alfa-2a | Chinese University of Hong Kong, Hoffmann-La Roche | Chronic Hepatitis B | 04/08 | 04/08 | | |
NCT00087646: REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy |
|
|
| Completed | 4 | 948 | US, Canada, Europe, RoW | Ribavirin, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 05/08 | 05/08 | | |
NCT02761629: Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus |
|
|
| Completed | 4 | 180 | RoW | Peg-Interferon Alpha-2A, Pegasys, Peg-IFN-Alpha-2A, Ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 05/08 | 05/08 | | |
NCT00917358: Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C |
|
|
| Completed | 4 | 42 | RoW | Pegylated interferon alfa-2a, Pegylated interferon alfa-2a (Pegasys, Hoffman-La Roche) | National Taiwan University Hospital, National Science Council, Taiwan | Hepatitis C | 06/08 | 06/08 | | |
NCT01519921: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B. |
|
|
| Completed | 4 | 150 | RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 06/08 | 06/08 | | |
NCT00495131: Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients |
|
|
| Completed | 4 | 308 | RoW | Pegylated interferon alfa-2a plus ribavirin, Pegasys plus Robatrol | National Taiwan University Hospital, National Science Council, Taiwan | Hepatitis C, Chronic | 06/08 | 07/08 | | |
NCT01258101: A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3 |
|
|
| Completed | 4 | 395 | Europe | peginterferon alfa-2a [Pegasys], ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 07/08 | 07/08 | | |
|
NCT02791269: A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program |
|
|
| Completed | 4 | 24 | RoW | Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Hepatitis B, Chronic | 07/08 | 07/08 | | |
NCT00291616: Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B |
|
|
| Completed | 4 | 52 | RoW | Pegylated Interferon-alpha2a, Thymosin alpha1 & Pegylated Interferon-alpha2a | Seoul National University Hospital, Roche Pharma AG, SciClone Pharmaceuticals | Chronic Hepatitis B | 08/08 | 08/08 | | |
PHOENIX, NCT00087633: Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C. |
|
|
| Completed | 4 | 115 | US | peginterferon alfa-2a [Pegasys], Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 10/08 | 10/08 | | |
NCT00630084: Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma |
|
|
| Completed | 4 | 120 | RoW | pegylated interferon alpha 2a and plus ribavirin, PEGASYS® | Kaohsiung Medical University Chung-Ho Memorial Hospital | Chronic Hepatitis C, Neoplasms | 10/08 | 10/08 | | |
| Terminated | 4 | 42 | Europe | Fast initiation procedure | Haukeland University Hospital, Bergen Prison, Norwegian Correctional Service, Hoffmann-La Roche | Chronic Hepatitis C | 01/09 | 01/09 | | |
NCT00203606: Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C |
|
|
| Completed | 4 | 66 | Canada | pegylated interferon alfa-2a ( Roche) and ribavirin | University of Calgary, Canadian Institutes of Health Research (CIHR), Roche Pharma AG | Hepatitis c | 01/09 | 08/11 | | |
|
NCT00800748 / 2005-003932-23: A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C |
|
|
| Completed | 4 | 372 | Europe, RoW | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 01/09 | 01/09 | | |
NCT00192647: A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection |
|
|
| Completed | 4 | 896 | Canada, RoW | PEG-IFN alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 03/09 | 03/09 | | |
NCT02598063: A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 255 | RoW | Adefovir dipivoxil, Lamivudine, Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Hepatitis B, Chronic | 04/09 | 04/09 | | |
NCT00353418 / 2005-005506-23: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection |
|
|
| Completed | 4 | 415 | US | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 04/09 | 04/09 | | |
NCT00629824: Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C |
|
|
| Completed | 4 | 250 | RoW | pegylated interferon alpha and plus ribavirin, PEGASYS® | Kaohsiung Medical University Chung-Ho Memorial Hospital | Chronic Hepatitis C | 04/09 | 04/09 | | |
NCT00394277 / 2005-005507-41: A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C |
|
|
| Completed | 4 | 1175 | US, Canada, Europe, RoW | peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 04/09 | 04/09 | | |
|
NCT00207311: Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus |
|
|
| Completed | 4 | 30 | US | Xenical, Pegasys, Copegus, Xenical (orlistat), Pegasys (PEG-Interferon alpha-2a), Xenicare Program, Xenical placebo, Pegasys (Peg interferon alpha-2a) | Brooke Army Medical Center, Hoffmann-La Roche, The Geneva Foundation | Fatty Liver, Hepatitis C | 05/09 | 05/09 | | |
NCT01787279: An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B |
|
|
| Completed | 4 | 59 | RoW | Peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 05/09 | 05/09 | | |
NCT00502099: Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4 |
|
|
| Completed | 4 | 217 | RoW | Pegylated interferon alpha 2a, Pegaesys, Ribavirin, Viracure, Pegylated interferon alpha 2 b plus ribavirin, PEG-Interon | Amr Hafez, Ain Shams University | Hepatitis C | 05/09 | 05/09 | | |
NCT00575224: Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9 |
|
|
| Completed | 4 | 60 | US | Pegylated interferon and ribavirin, Pegasys and Copegus | Pacific Health Foundation, Hoffmann-La Roche | Chronic Hepatitis C, Asian Americans, Novel Genotypes, Treatment | 09/09 | 09/09 | | |
NCT00707772: Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection |
|
|
| Completed | 4 | 400 | RoW | PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin), Peginterferon Alfa-2a (40KD) Plus COPEGUS, Peginterferon Alfa-2a (40KD) plus COPEGUS | Baqiyatallah Medical Sciences University, Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Tehran Hepatitis Center, Guilan University of Medical Sciences, Tabriz Research Center for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Iran University of Medical Sciences | Hepatitis C, Hemophilia | 09/09 | 09/09 | | |
NCT00707850: Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection |
|
|
| Completed | 4 | 300 | RoW | PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin), Peginterferon Alfa-2a (40KD) plus COPEGUS | Baqiyatallah Medical Sciences University, Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Tehran Hepatitis Center, Guilan University of Medical Sciences, Tabriz Research Center for Gastroenterology and Liver Diseases | Hepatitis C, Thalassemia | 09/09 | 09/09 | | |
NCT00487747: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B. |
|
|
| Completed | 4 | 18 | RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 10/09 | 10/09 | | |
NCT00614471: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B. |
|
|
| Completed | 4 | 219 | RoW | Entecavir, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 10/09 | 10/09 | | |
NCT00940420: A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C |
|
|
| Completed | 4 | 2695 | RoW | Copegus (ribavirin), peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 11/09 | 11/09 | | |
NCT01195181: Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice. |
|
|
| Completed | 4 | 506 | Europe | peginterferon plus ribavirin, Pegasys, PegIntron, Copegus, Rebetol | Azienda Ospedaliera di Padova, Regione Veneto, University of Padova | Hepatitis C Virus, Chronic Liver Disease, Viral Hepatitis, Therapeutic Uses, Antiviral Agents | 12/09 | 08/10 | | |
RelapC, NCT00641654 / 2006-003409-18: Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin |
|
|
| Terminated | 4 | 75 | Europe | Pegylated interferon alfa-2a and ribavirin, Pegasys, Copegus | Göteborg University, Hoffmann-La Roche | Chronic Hepatitis C | 12/09 | 12/09 | | |
NCT00056862: Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 |
|
|
| Completed | 4 | 58 | US | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Hepatitis C | 01/10 | 06/10 | | |
NCT00436163 / 2006-005370-49: A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 39 | Europe | Peginterferon alfa-2a, Pegasys® | Hoffmann-La Roche | Hepatitis B, Chronic | 05/10 | 05/10 | | |
| Completed | 4 | 71 | Europe | Pegylated interferon alfa-2a and Ribavirin, Pegasys, Copegus, Pegylated interferon alfa 2a and Ribavirin, Pegasis (TM), Copegus (TM) | Sociedad Andaluza de Enfermedades Infecciosas | Hepatitis C, Chronic, HIV Infections | 05/10 | 05/10 | | |
NCT00132210: Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients |
|
|
| Completed | 4 | 200 | Europe | pegylated interferon, Pegasys, PegIntron, Copegus, Rebetol | University Hospital, Bonn | Hepatitis C, HIV Infections | 06/10 | 06/10 | | |
| Completed | 4 | 167 | RoW | Pegylated Interferon alfa 2a, pegasys, Ribavirin (HIV conifected patients only) | Kirby Institute, The University of New South Wales, National Institutes of Health (NIH) | Hepatitis C | 06/10 | 06/10 | | |
TTG1, NCT00910975: Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C |
|
|
| Completed | 4 | 100 | Europe | Peg-interferon-alfa2a (Pegasys), Pegasys, Ribavirin (Copegus) | Göteborg University, Sahlgrenska University Hospital, Sweden, Sodra Alvsborgs Hospital, Skaraborg Hospital, Uddevalla Hospital, Skane University Hospital, Lund University Hospital, Karolinska University Hospital | Chronic Hepatitis C, Genotype 1 | 06/10 | 09/11 | | |
NCT00245414: Trial of Pegasys® in Patients With Chronic Hepatitis C |
|
|
| Completed | 4 | 108 | Japan | Pegasys® | Chugai Pharmaceutical | Chronic Hepatitis C | 07/10 | 07/10 | | |
NCT00412334: SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1. |
|
|
| Completed | 4 | 104 | Europe | Copegus, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 09/10 | 09/10 | | |
|
NCT00435825 / 2006-000870-63: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB). |
|
|
| Completed | 4 | 551 | US, Europe, RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 12/10 | 12/10 | | |
NCT00545233: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance. |
|
|
| Completed | 4 | 155 | US | peginterferon alfa-2a [Pegasys], Pegasys, ribavirin [Copegus], Copegus, Pioglitazone, Actos | Hoffmann-La Roche | Hepatitis C, Chronic | 12/10 | 12/10 | | |
CONTRA, NCT01684787: Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients |
|
|
| Completed | 4 | 80 | Europe | Peginterferon alfa-2a + ribavirin in normal ALT, Pegasys + ribavirin, Peginterferon alfa-2a + ribavirin in elevated ALT | Miguel Santin | Chronic Hepatitis C | 05/11 | 06/11 | | |
NCT00474955: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure. |
|
|
| Completed | 4 | 27 | RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 06/11 | 06/11 | | |
NCT00926614: Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba |
|
|
| Completed | 4 | 20 | US | pioglitazone (Actos), Actos, atorvastatin (Lipitor), Lipitor | Brooke Army Medical Center | Hepatitis c | 06/11 | 12/11 | | |
NCT01378104: 100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC) |
|
|
| Completed | 4 | 178 | RoW | peginterferon alfa 2a (pegasys), Roche, peginterferon alfa-2a (pegasys) | The Catholic University of Korea, Ulsan University Hospital, National Health Insurance Service Ilsan Hospital, Inje University, Soonchunhyang University Hospital, Yonsei University, Chungnam National University, Keimyung University, Kyungpook National University Hospital, Konyang University Hospital, Inha University Hospital, Hallym University Medical Center | Sustained Virologic Response, IL28B Polymorphism | 09/11 | 09/12 | | |
DARGEN-3, NCT00830609: High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 |
|
|
| Completed | 4 | 101 | Europe | Peginterferon alfa 2 A, Pegasys, Peginterferon alfa 2 A, ribavirin + Epo Beta, ribavirin, peginterferon alfa 2 a, Epoetin beta, Peginterferon alfa 2 | Dr. Conrado Fernandez | Chronic Hepatitis C | 09/11 | 12/11 | | |
| Completed | 4 | 190 | Europe | Pegasys, Ribavirin, epoetin beta [NeoRecormon] | Hoffmann-La Roche | Anemia | 11/11 | 11/11 | | |
NCT01596517: Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C |
|
|
| Completed | 4 | 272 | RoW | Peginterferon alfa-2a plus ribavirin for HCV genotype 1, Pegasys, Copegus, Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3 | Asan Medical Center, Samsung Medical Center, Severance Hospital, Gangnam Severance Hospital, Seoul St. Mary's Hospital, Korea University Guro Hospital | Chronic Hepatitis C | 12/11 | 05/12 | | |
NCT00881582: Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients |
|
|
| Completed | 4 | 32 | RoW | Pegylated interferon alfa-2a plus ribavarin, Pegasys®, F. Hoffman-LaRoche, Copegus®, F. Hoffman-LaRoche | King Abdulaziz Medical City, Riyadh Military Hospital, King Faisal Specialist Hospital & Research Center | Chronic Hepatitis C, Renal Transplant | 12/11 | 12/11 | | |
NCT00940485: A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 200 | RoW | entecavir, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 12/11 | 12/11 | | |
NCT00922779: A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C |
|
|
| Completed | 4 | 6661 | RoW | peginterferon alfa-2a [Pegasys], ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 06/12 | 06/12 | | |
NCT01447420: A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) |
|
|
| Completed | 4 | 129 | RoW | peginterferon alfa-2a, ribavirin [Copegus] | Hoffmann-La Roche | Hepatitis C, Chronic | 11/12 | 11/12 | | |
NCT00977054: Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load |
|
|
| Terminated | 4 | 59 | RoW | DFPP + Peg-IFN + RBV, DFPP: Plasmaflo + Cascadeflo EC-50W (Asahi), Peg-IFN alfa-2a: Pegasys (Hoffman La-Roche), RBV: Copegus (Hoffman La-Roche), Peg-IFN + RBV | National Taiwan University Hospital, National Science Council, Taiwan, Department of Health, Executive Yuan, R.O.C. (Taiwan) | Hepatitis C | 12/12 | 12/12 | | |
NCT01086085: A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive |
|
|
| Completed | 4 | 265 | RoW | Adefovir, peginterferon alfa-2a [PEGASYS] | Hoffmann-La Roche, Major Science and Technology Special Project of China Eleventh Five-year | Hepatitis B, Chronic | 03/13 | 03/13 | | |
NCT01033448: A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response |
|
|
| Completed | 4 | 59 | RoW | COPEGUS, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 06/13 | 06/13 | | |
NCT01429792: A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) |
|
|
| Completed | 4 | 1013 | RoW | peginterferon alfa-2a [Pegasys], ribavirin [Copegus] | Hoffmann-La Roche | Hepatitis C, Chronic | 06/13 | 06/13 | | |
| Completed | 4 | 184 | Europe, RoW | pegylated interferon a-2a, Pegasys, Entecavir, Baraclude | Foundation for Liver Research | Chronic Hepatitis B | 07/13 | 07/13 | | |
NCT00491244: Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C |
|
|
| Completed | 4 | 377 | RoW | Peginterferon alfa-2a and ribavirin, Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche), Ribavirin (Copegus, F. Hoffman-LaRoche), Peginterferon alfa-2a | National Taiwan University Hospital, National Science Council, Taiwan, Department of Health, Executive Yuan, R.O.C. (Taiwan) | Chronic Hepatitis C | 09/13 | 09/13 | | |
|
NCT02641379: A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) |
|
|
| Completed | 4 | 737 | Europe | Peginterferon alfa-2a, Pegasys, Ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 11/13 | 11/13 | | |
NCT00540345: Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C |
|
|
| Completed | 4 | 300 | RoW | pegylated interferon alpha 2a and plus ribavirin, PEGASYS®, Pegylated interferon alfa-2a and ribavirin, pegylated interferon alpha 2a and ribavirin | Kaohsiung Medical University Chung-Ho Memorial Hospital | Chronic Hepatitis C | 12/13 | 12/13 | | |
NCT01585324 / 2011-001256-10: A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) |
|
|
| Completed | 4 | 30 | Europe | peginterferon alfa-2a [Pegasys], ribavirin [Copegus] | Hoffmann-La Roche | Hepatitis C, Chronic | 01/14 | 01/14 | | |
NCT00532701: Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR |
|
|
| Completed | 4 | 880 | RoW | Peg-IFN + WB RBV for 16 weeks, Pegasys plus Copegus, Peg-IFN + LD RBV for 16 weeks, Peg-IFN + WB RBV for 24 weeks, Peg-IFN + WB RBV for 48 weeks, Peg-IFN + LD RBV for 24 weeks | National Taiwan University Hospital, National Science Council, Taiwan, Department of Health, Executive Yuan, R.O.C. (Taiwan) | Chronic Hepatitis C | 03/14 | 03/14 | | |
NCT01467492: Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C |
|
|
| Terminated | 4 | 121 | US | Telaprevir, Incivek, VX-950, Ribavirin, Copegus®, RBV, Pegylated Interferon Alfa-2a, Pegasys®, Peg-IFN-Alfa-2a | Vertex Pharmaceuticals Incorporated | Hepatitis C | 05/14 | 05/14 | | |
|
NCT01591460 / 2011-004810-41: A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C |
|
|
| Completed | 4 | 165 | Europe | boceprevir, peginterferon alfa-2a [Pegasys], ribavirin (Copegus] | Hoffmann-La Roche | Hepatitis C, Chronic | 06/14 | 06/14 | | |
NCT01405027: Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy |
|
|
| Completed | 4 | 197 | US | Educational Intervention, Peg-Intron, Pegasys, Victrelis, Pegylated interferon alfa 2B, Pegylated interferon alfa 2A, Boceprevir, Ribavirin, Patient education and management skills training | Chronic Liver Disease Foundation, SCRI Development Innovations, LLC, Merck Sharp & Dohme LLC | Chronic Hepatitis C, Genotype 1 | 07/14 | 07/14 | | |
|
NCT01277601 / 2010-024586-45: Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B |
|
|
| Completed | 4 | 751 | US, Canada, Europe, RoW | TDF, Viread®, Peg-IFN, Pegasys® | Gilead Sciences | Chronic Hepatitis B | 08/14 | 07/15 | | |
NCT00922207: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 280 | RoW | Adefovir, Entecavir, Placebo, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 09/14 | 09/14 | | |
NCT00927082: A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 383 | RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 11/14 | 11/14 | | |
NCT01179594: A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B. |
|
|
| Withdrawn | 4 | 0 | NA | entecavir, peginterferon alfa-2a [Pegasys], placebo | Hoffmann-La Roche | Hepatitis B, Chronic | 11/14 | 11/14 | | |
| Completed | 4 | 82 | RoW | Peginterferon alfa-2a, Pegasys, Ribavirin | Kirby Institute | Acute Hepatitis C | 06/15 | 06/15 | | |
| Completed | 4 | 6 | Europe | Pegylated interferon alpha-2a, Pegasys®, Roche, Ribavirin, Copegus®, Roche, Boceprevir, Victrelis®, MSD | Markus Peck-Radosavljevic, Medical University of Vienna | Hepatitis C, Chronic, HIV | 06/15 | 06/15 | | |
|
|
| Completed | 4 | 14 | RoW | TPV/PEG-IFN/RBV, Telaprevir brand name: INCIVO, Ribavirin brand name: COPEGUS, PEG-IFN brand name: PEGASYS | Kirby Institute, Janssen-Cilag Ltd. | Hepatitis C, Chronic | 11/15 | 01/16 | | |
NCT02377856: Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection |
|
|
| Completed | 4 | 20 | RoW | pegylated interferon alpha 2a, ribavirin, PEGASYS® | Kaohsiung Medical University Chung-Ho Memorial Hospital | Acute Hepatitis C | 02/16 | 02/16 | | |
PBMC, NCT00680173: Peripheral Blood Mononuclear Cell () Gene Expression in HCV Genotype 1 Patients |
|
|
| Completed | 4 | 30 | RoW | pegylated interferon alpha 2a and plus ribavirin, PEGASYS® | Kaohsiung Medical University Chung-Ho Memorial Hospital | Chronic Hepatitis C | 03/16 | 03/16 | | |
NCT02480686: Neutrino Regimen for Treatment-experienced HCV GT1 Patients |
|
|
| Completed | 4 | 32 | RoW | SOF+PEG+RBV, GS-7977, PSI-7977, Sovaldi®, Pegasys®, Copegus® | Humanity and Health Research Centre, Beijing 302 Hospital | Chronic Hepatitis C Infection | 08/16 | 08/16 | | |
NCT01937728: Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1) |
|
|
| Completed | 4 | 542 | RoW | A: Peg-interferon alpha-2a & Ribavirin, Pegasys & Robatrol, B: Peg-interferon alpha-2a & Ribavirin, C: Peg-interferon alpha-2a & Ribavirin, Pegasys, Robatrol, D: Peg-interferon alpha-2a & Ribavirin, PEGASYS, Robatrol, E: Peg-interferon alpha-2a & Ribavirin, F: Peg-interferon alpha-2a & Ribavirin | Kaohsiung Medical University Chung-Ho Memorial Hospital | Hepatitis C | 10/16 | 12/16 | | |
NCT01938781: Optimized Treatment and Regression of HBV-induced Liver Fibrosis |
|
|
| Completed | 4 | 400 | RoW | entecavir, entecavir dispersible tablets, Peg-IFN, Pegasys | Beijing Friendship Hospital, Peking University People's Hospital, RenJi Hospital, Peking University, Shanghai Zhongshan Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Public Health Clinical Center, Nanfang Hospital of Southern Medical University, Sir Run Run Shaw Hospital, Beijing YouAn Hospital, Peking University First Hospital, Beijing 302 Hospital, Peking Union Medical College Hospital, Beijing Ditan Hospital, Beijing Tiantan Hospital, Huashan Hospital, Tongji Hospital, Tang-Du Hospital, Fifth Hospital of Shijiazhuang City, Logistics University of Chinese People's Armed Police Forces, The First Affiliated Hospital of Shanxi Medical University, The Affiliated Hospital of Yanbian University | Liver Fibrosis | 12/16 | 12/16 | | |
E+VIP, NCT02097004: Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection |
|
|
| Completed | 4 | 111 | RoW | Peginterferon alfa-2a, Pegasys, HBV vaccination, Euvax B Inj, Entecavir, Baracrude | Seoul National University Hospital | Hepatitis B, Chronic | 01/18 | 03/18 | | |
NCT03084250: The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC |
|
|
| Active, not recruiting | 4 | 150 | RoW | Peginterferon Alfa-2A, Pegasys, Adefovir, entecavir,tenofovir, either of them | Shanghai Nanhui Nanhua Hospital | Hepatitis B | 04/23 | 12/23 | | |
